# Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

> **NCT00557492** · PHASE2 · COMPLETED · sponsor: **Amer Zureikat** · enrollment: 59 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Avastin (bevacizumab)
- **DRUG:** Gemzar (Gemcitabine)
- **RADIATION:** external beam radiotherapy

## Key facts

- **NCT ID:** NCT00557492
- **Lead sponsor:** Amer Zureikat
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2012-03
- **Final completion:** 2016-12
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00557492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00557492, "Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00557492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*